Aptose Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	4.1	6.71	9.25	36.97	39.11
Short-Term Investments	-	-	-	9.99	40.01
Cash & Short-Term Investments	4.1	6.71	9.25	46.96	79.13
Cash Growth	-38.93%	-27.51%	-80.30%	-40.65%	-35.35%
Other Current Assets	2.35	2.82	2.64	2.56	2.61
Total Current Assets	6.45	9.53	11.89	49.52	81.74
Net Property, Plant & Equipment	0.18	0.6	1.1	1.51	0.79
Other Long-Term Assets	3.39	-	-	-	-
Total Assets	10.01	10.13	12.99	51.03	82.53
Accounts Payable	2.91	1.26	6.05	6.33	1.7
Accrued Expenses	6.2	2.77	8.83	5.66	6.02
Current Portion of Leases	0.19	0.43	0.39	0.3	0.46
Other Current Liabilities	0.86	0.02	-	-	-
Total Current Liabilities	9.31	4.46	15.27	12.28	8.17
Long-Term Debt	27.02	10	-	-	-
Long-Term Leases	-	0.19	0.62	1	0.12
Total Long-Term Liabilities	27.87	10.21	0.62	1	0.12
Total Liabilities	37.18	14.67	15.89	13.29	8.29
Common Stock	459.77	457.4	444.81	437.52	437.39
Additional Paid-in Capital	83.81	83.34	72.15	68.87	63.67
Accumulated Other Comprehensive Income	-4.32	-4.32	-4.32	-4.32	-4.32
Retained Earnings	-566.44	-540.97	-515.54	-464.33	-422.51
Shareholders' Equity	-27.17	-4.54	-2.9	37.74	74.24
Total Liabilities & Equity	10.01	10.13	12.99	51.03	82.53
Total Debt	27.21	10.62	1.02	1.3	0.57
Net Cash (Debt)	-23.12	-3.91	8.24	45.66	78.55
Net Cash Growth	-	-	-81.96%	-41.88%	-35.25%
Net Cash Per Share	-9.45	-5.60	36.58	222.68	396.80
Book Value	-27.17	-4.54	-2.9	37.74	74.24
Book Value Per Share	-11.10	-6.50	-12.88	184.07	374.99
Tangible Book Value	-27.17	-4.54	-2.9	37.74	74.24
Tangible Book Value Per Share	-11.10	-6.50	-12.88	184.07	374.99

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.